News

Decades-Old Blood Thinner May Double as a SARS-CoV-2 Cure

Decades-Old Blood Thinner May Double as a SARS-CoV-2 Cure

The research team at Rensselaer Polytechnic Institute has hypothesized that heparin, a 78-year old blood thinner may be enough to block the viral spike that invades cells as a result of SARS-CoV-2. The heparin binds to the virus, making it a potential “decoy” which might neutralize the virus. In order to confirm this theory, clinical trials are necessary. Yourway can independently support all aspects of clinical trials. Our years of experience, proven track record, and global network of GMP depots are all that’s needed to support the full scope of all clinical supply chain needs.

Back to Index
Media

Upcoming Event

IQPC CTS

August 24-26, 2020
Brussels, Belgium

Media

Articles

The New Normal in Clinical Trial Protection

Open chat
Come chat with us!
Hello! How can I help you?